

Resource Summary Report

Generated by [SPARC SAWG](#) on Jul 30, 2026

ChEMBL

RRID:SCR_014042

Type: Tool

Proper Citation

ChEMBL (RRID:SCR_014042)

Resource Information

URL: <https://www.ebi.ac.uk/chembl/>

Proper Citation: ChEMBL (RRID:SCR_014042)

Description: Collection of bioactive drug-like small molecules that contains 2D structures, calculated properties and abstracted bioactivities. Used for drug discovery and chemical biology research. Clinical progress of new compounds is continuously integrated into the database.

Synonyms: ChEMBLdb, ChEMBL, ChEMBL Database

Resource Type: data or information resource, database

Defining Citation: [PMID:21948594](#)

Keywords: database, compound, data, bioassay, bioactive, molecule, drug, discovery

Funding: Wellcome Trust ;
EMBL Member States ;
Medicines for Malaria Ventures ;
EU Innovative Medicines Initiative ;
GSK ;
Syngenta ;
Pfizer

Availability: Public, Free, Freely available, Acknowledgement requested

Resource Name: ChEMBL

Resource ID: SCR_014042

Alternate IDs: r3d100010539

Alternate URLs: <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>, <https://doi.org/10.17616/R3C320>

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260729T044341+0000

Ratings and Alerts

No rating or validation information has been found for ChEMBL.

No alerts have been found for ChEMBL.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2433 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Zhang Q, et al. (2026) Synergistic effects of Akebia saponin D and Semaglutide on diabetic nephropathy and osteoporosis via the Klotho/p53 signaling axis. International journal of molecular medicine, 57(1).

Wang X, et al. (2025) Integrative machine learning and transcriptomic analysis identifies key molecular targets in MNPN-associated oral squamous cell carcinoma pathogenesis. Frontiers in bioinformatics, 5, 1664576.

Malarvizhi GL, et al. (2025) Rationally Designed Functionalized Phytochemical-Conjugated Fullerene Quantum Dots Inhibiting Viral Chaperone Activity and RNA-Dependent RNA Polymerase in Nipah Virus. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 39(15), e70890.

Puleo N, et al. (2025) Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. Molecular cancer therapeutics, 24(4), 639.

Lyu TT, et al. (2025) The sodium-glucose co-transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF

receptor-?. British journal of pharmacology.

Du H, et al. (2025) CovalentInDB 2.0: an updated comprehensive database for structure-based and ligand-based covalent inhibitor design and screening. Nucleic acids research, 53(D1), D1322.

Duong Nguyen TT, et al. (2025) PGxDB: an interactive web-platform for pharmacogenomics research. Nucleic acids research, 53(D1), D1486.

Murray JD, et al. (2025) Establishing a Pharmacoinformatics Repository of Approved Medicines: A Database to Support Drug Product Development. Molecular pharmaceutics, 22(1), 408.

Zheng T, et al. (2025) Data-driven parametrization of molecular mechanics force fields for expansive chemical space coverage. Chemical science, 16(6), 2730.

Zheng H, et al. (2025) Dissecting Causal Relationships Between Antihypertensive Drug, Gut Microbiota, and Type 2 Diabetes Mellitus and Its Complications: A Mendelian Randomization Study. Journal of clinical hypertension (Greenwich, Conn.), 27(1), e14968.

Xu Y, et al. (2025) Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology. PloS one, 20(1), e0316481.

Qian L, et al. (2025) Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta-9-Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes. Clinical and translational science, 18(1), e70119.

, et al. (2025) Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell, 188(3), 640.

Schallmayer E, et al. (2025) Chemogenomics for steroid hormone receptors (NR3). Communications chemistry, 8(1), 29.

Viesi E, et al. (2025) APBIO: bioactive profiling of air pollutants through inferred bioactivity signatures and prediction of novel target interactions. Journal of cheminformatics, 17(1), 13.

Wan Z, et al. (2025) Applications of Artificial Intelligence in Drug Repurposing. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(14), e2411325.

Wilson M, et al. (2025) SELFprot: Effective and Efficient Multitask Finetuning Methods for Protein Parameter Prediction. Journal of chemical information and modeling, 65(7), 3226.

Ishida S, et al. (2025) Large language models open new way of AI-assisted molecule design for chemists. Journal of cheminformatics, 17(1), 36.

Han H, et al. (2025) Employing Automated Machine Learning (AutoML) Methods to Facilitate the In Silico ADMET Properties Prediction. Journal of chemical information and modeling, 65(7), 3215.

AbdulHameed MDM, et al. (2025) MONSTROUS: a web-based chemical-transporter interaction profiler. Frontiers in pharmacology, 16, 1498945.